FindTrial
Sign In

Comparison of two methods of naloxone administration on improvement of clinical manifestations in patients with opium poisoning.

Comparison effects of two methods of naloxone administration on improvement of clinical manifestations in patients with opium toxicity.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110514006481N14
Enrollment
60
Registered
2020-11-28
Start date
2020-12-21
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid dependence. Opioid dependence with intoxication

Interventions

Intervention 1: Intervention group: Administration of naloxone hydrochloride (Tolidaru Pharmaceutical Co, Tehran, Iran) at dose of 2 mg with nebulizer mask that diluted in 3 ml normal saline. Interven

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to No maximum

Inclusion criteria

Inclusion criteria: Known opium toxicity Spontaneous breathing more than 6 breath per minute Age above 15 years old

Exclusion criteria

Exclusion criteria: Nose bleeding Unstable hemodynamic Allergy to naloxone

Design outcomes

Primary

MeasureTime frame
Level of consciousness. Timepoint: 5 min, 10 min, 15 min and 20 min after naloxone administration. Method of measurement: Glasgow Coma Scale.;Vital signs. Timepoint: 5 min, 10 min and 20 min after naloxone administration. Method of measurement: Ward monitor.;Clinical opiate withdrawal signs. Timepoint: 5 min, 10 min and 20 min after naloxone administration. Method of measurement: Clinical Opiate Withdrawal Scale (COWS).—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Soleimani

Semnan University of Medical Sciences

Soli257@yahoo.com0098 23 3354190

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026